Developer docs
API playgroundTry for free, no card

Search company profiles

TissueGen

Full company profile

uuid000rfpr

Namestring
TissueGen
Legal namestring
TissueGen, Inc.
Websiteurl
tissuegen.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

TissueGen, Inc. is a privately held drug delivery technology company headquartered in Irving, Texas (Dallas metro), founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at the University of Texas Southwestern Medical Center and the University of Texas at Arlington. The company develops a proprietary two-phase emulsion encapsulation platform enhanced with nanotechnology that enables sensitive biological therapeutics — including antibodies, cytokines, and growth factors — to be loaded into biodegradable polymer delivery systems while preserving greater than 90% of their biological activity post-processing. The core technical problem solved is the historical incompatibility between harsh fiber extrusion conditions and fragile biologics, originally addressed by founder Kevin D. Nelson, PhD.

The product portfolio spans four delivery formats built on the same platform architecture: wet-extruded drug-eluting biodegradable fibers (the original format, capable of release over days to months and formable into woven, knitted, braided, or independent suture constructs); drug-eluting shape-set coils that create three-dimensional drug concentration gradients; a microparticle platform for injectable delivery of water-soluble drugs via small-gauge needles; and a nanoparticle process for protecting and distributing therapeutics into polymer solutions. IP coverage includes 30 patents and applications across 19 jurisdictions, with granted claims on drug-eluting self-retaining sutures, biomolecule conformation preservation, self-expanding medical devices, and the core drug-releasing biodegradable fiber process.

TissueGen operates a B2B enterprise technology licensing and partnership model, targeting pharmaceutical and biotechnology companies that need advanced delivery formats for complex or temperature-sensitive therapeutics. The company is not a product retailer; it monetizes its platform through licensing and co-development arrangements with drug developers. The team consists of approximately 15 personnel across executive management, a four-person board of directors (including the founder), a three-person advisory board, and technical staff. A notable capital event was a $42 million patent infringement verdict awarded jointly to TissueGen and the University of Texas System against Boston Scientific, evidencing enforceable IP value but not recurring revenue.

Short descriptiontext

TissueGen is a private Dallas-area drug delivery technology company licensing a proprietary two-phase emulsion platform that encapsulates sensitive biologics into biodegradable fibers, coils, microparticles, and nanoparticles for pharmaceutical and biotechnology partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biodegradable drug delivery, polymer drug delivery, extended-release biologics, pharmaceutical drug delivery, biologics encapsulation
Industry1 code
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Plastics Material and Resin Manufacturing325211
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Miscellaneous Plastics Products3080
Product category
Pharmaceutical Drug Delivery Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Licensing
TypeLicensing Royalties
Description

Licensing proprietary drug delivery technology and encapsulation platform to pharmaceutical and biotech companies for development of extended-release therapeutics.

tissuegen.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TissueGen develops a proprietary two-phase drug delivery platform that uses biodegradable polymers and nanotechnology to encapsulate sensitive biological therapeutics — including antibodies, growth factors, cytokines, and plasmid DNA — into extended-release formats. The company manufactures and licenses drug-eluting fibers, drug-eluting coils, microparticles, and nanoparticles designed to deliver biologics without degradation across nerve, vascular, and ophthalmic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Greater than 90% preserved biological activity post-fiber extrusion for several antibodies and growth factors
+1 more record
Product overview1 text field

TissueGen is a drug delivery technology company that developed a proprietary encapsulation platform enabling the delivery of complex therapeutics, from small molecules to temperature and chemically sensitive biologics such as antibodies, cytokines, and growth factors. The platform comprises four distinct delivery formats: Drug-Eluting Fibers (biodegradable extruded fibers for extended release over days to months), Drug-Eluting Coils (shape-set fibers providing 3D drug concentration gradients), Microparticles (injectable particles for water-soluble drugs), and Nanoparticles (for protecting and distributing therapeutic agents into polymer solutions). The company uses approved biodegradable polymers and a two-phase emulsion system incorporating nanotechnology to preserve biological activity during processing.

Product and service5 records
1Drug-Eluting Fibers
CategoryDrug delivery systems
2Drug-Eluting Coils
CategoryDrug delivery systems
3Microparticle Platform
CategoryDrug delivery systems
4Nanoparticle Platform
CategoryDrug delivery systems
5Proprietary Encapsulation Technology Licensing
CategoryTechnology licensing and contract development
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2000-01-01
Description

TissueGen was founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at UT Southwestern Medical Center at Dallas and UT Arlington. Initial technology was developed by founder Dr. Kevin Nelson at these institutions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pacira commercializes proprietary extended-release injectable drug delivery technologies and serves as a benchmark for how a polymer-based delivery platform can scale into a commercial pharma business — a relevant aspirational peer for TissueGen.

TypeBroad incumbent
Description

Ashland's Life Sciences division provides pharmaceutical excipients, controlled-release polymers, and drug-delivery formulation support, competing with TissueGen for pharma licensing and co-development engagements.

TypeBroad incumbent
Description

DSM Biomedical supplies biomedical-grade polymers and drug-eluting device materials to the medical and pharmaceutical industries, overlapping with TissueGen's biodegradable delivery formats and licensing-style customer model.

4Lubrizol Life Science
TypeBroad incumbent
Description

Lubrizol Life Science produces engineered polymers and excipients for pharmaceutical drug delivery, including controlled-release systems — a broad incumbent serving the same pharma licensing customer base as TissueGen.

TypeBroad incumbent
Description

Evonik's Health Care division supplies RESOMER biodegradable polymers and formulation services for parenteral drug delivery, including sustained-release microparticles and implants — directly overlapping with TissueGen's polymer-based extended-release platform.

TypeDirect peer
Description

PolyPid develops polymer-based drug delivery platforms for localized, prolonged therapeutic release — directly comparable in product architecture and B2B pharma partnership strategy.

7Bezwada Biomedical
TypeEmerging player
Description

Bezwada Biomedical develops absorbable polymers and bioabsorbable medical products, including drug-eluting formats, with a smaller-scale, innovation-driven profile comparable to TissueGen's specialist platform approach.

TypeDirect peer
Description

Innocore specializes in biodegradable polymeric drug delivery systems including injectable sustained-release formulations — a closely aligned business model and technology stack to TissueGen's microparticle and fiber platform.

TypeBroad incumbent
Description

Corbion produces bioresorbable polymers (PURASORB) used in drug delivery and medical devices, and supplies biomaterial inputs comparable to TissueGen's approved-polymer foundation for extended-release therapeutics.

TypeDirect peer
Description

Surmodics develops drug-delivery coatings and polymer-based combination products for medical devices and pharmaceuticals, making it a direct peer in polymer-encapsulated, sustained-release therapeutic delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TissueGen

Pharmaceutical Drug Delivery Technologytissuegen.com

TissueGen is a private Dallas-area drug delivery technology company licensing a proprietary two-phase emulsion platform that encapsulates sensitive biologics into biodegradable fibers, coils, microparticles, and nanoparticles for pharmaceutical and biotechnology partners.

What TissueGen does

TissueGen, Inc. is a privately held drug delivery technology company headquartered in Irving, Texas (Dallas metro), founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at the University of Texas Southwestern Medical Center and the University of Texas at Arlington. The company develops a proprietary two-phase emulsion encapsulation platform enhanced with nanotechnology that enables sensitive biological therapeutics — including antibodies, cytokines, and growth factors — to be loaded into biodegradable polymer delivery systems while preserving greater than 90% of their biological activity post-processing. The core technical problem solved is the historical incompatibility between harsh fiber extrusion conditions and fragile biologics, originally addressed by founder Kevin D. Nelson, PhD.

The product portfolio spans four delivery formats built on the same platform architecture: wet-extruded drug-eluting biodegradable fibers (the original format, capable of release over days to months and formable into woven, knitted, braided, or independent suture constructs); drug-eluting shape-set coils that create three-dimensional drug concentration gradients; a microparticle platform for injectable delivery of water-soluble drugs via small-gauge needles; and a nanoparticle process for protecting and distributing therapeutics into polymer solutions. IP coverage includes 30 patents and applications across 19 jurisdictions, with granted claims on drug-eluting self-retaining sutures, biomolecule conformation preservation, self-expanding medical devices, and the core drug-releasing biodegradable fiber process.

TissueGen operates a B2B enterprise technology licensing and partnership model, targeting pharmaceutical and biotechnology companies that need advanced delivery formats for complex or temperature-sensitive therapeutics. The company is not a product retailer; it monetizes its platform through licensing and co-development arrangements with drug developers. The team consists of approximately 15 personnel across executive management, a four-person board of directors (including the founder), a three-person advisory board, and technical staff. A notable capital event was a $42 million patent infringement verdict awarded jointly to TissueGen and the University of Texas System against Boston Scientific, evidencing enforceable IP value but not recurring revenue.

TissueGen firmographics

Firmographics
Name
TissueGen
Legal name
TissueGen, Inc.
Website
https://tissuegen.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
TissueGen is a private Dallas-area drug delivery technology company licensing a proprietary two-phase emulsion platform that encapsulates sensitive biologics into biodegradable fibers, coils, microparticles, and nanoparticles for pharmaceutical and biotechnology partners.
Ownership category
akta.pro rank

TissueGen industry classification

Industry
Product category
Pharmaceutical Drug Delivery Technology
NAICS
Medical Equipment and Supplies Manufacturing (3391), Plastics Material and Resin Manufacturing (325211)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Miscellaneous Plastics Products (3080)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biodegradable drug delivery
  • Polymer drug delivery
  • Extended-release biologics
  • Pharmaceutical drug delivery
  • Biologics encapsulation

Where TissueGen is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TissueGen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Technology Licensing: Licensing proprietary drug delivery technology and encapsulation platform to pharmaceutical and biotech companies for development of extended-release therapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

TissueGen product offering

Product offering

Core offering

TissueGen develops a proprietary two-phase drug delivery platform that uses biodegradable polymers and nanotechnology to encapsulate sensitive biological therapeutics — including antibodies, growth factors, cytokines, and plasmid DNA — into extended-release formats. The company manufactures and licenses drug-eluting fibers, drug-eluting coils, microparticles, and nanoparticles designed to deliver biologics without degradation across nerve, vascular, and ophthalmic applications.

Product overview

TissueGen is a drug delivery technology company that developed a proprietary encapsulation platform enabling the delivery of complex therapeutics, from small molecules to temperature and chemically sensitive biologics such as antibodies, cytokines, and growth factors. The platform comprises four distinct delivery formats: Drug-Eluting Fibers (biodegradable extruded fibers for extended release over days to months), Drug-Eluting Coils (shape-set fibers providing 3D drug concentration gradients), Microparticles (injectable particles for water-soluble drugs), and Nanoparticles (for protecting and distributing therapeutic agents into polymer solutions). The company uses approved biodegradable polymers and a two-phase emulsion system incorporating nanotechnology to preserve biological activity during processing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug-Eluting Fibers
  • Drug-Eluting Coils
  • Microparticle Platform
  • Nanoparticle Platform
  • Proprietary Encapsulation Technology Licensing

Quantifiable outcome

  • Greater than 90% preserved biological activity post-fiber extrusion for several antibodies and growth factors
  • +1 more outcomes

Companies that use TissueGen

Customer profile

Segments2 records

Ideal customer profiles2 records

TissueGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

TissueGen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of Texas Southwestern Medical Center at DallascoreStrategic or Co-development Partner · 1 January 2000TissueGen was founded in 2000 as a spin-out of the Joint Program of Biomedical Engineering at UT Southwestern Medical Center at Dallas and UT Arlington. Initial technology was developed by founder Dr. Kevin Nelson at these institutions.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

TissueGen competitors and assessment

Company assessment

Broad incumbents

  • Pacira BioSciences: Pacira commercializes proprietary extended-release injectable drug delivery technologies and serves as a benchmark for how a polymer-based delivery platform can scale into a commercial pharma business — a relevant aspirational peer for TissueGen.
  • Ashland: Ashland's Life Sciences division provides pharmaceutical excipients, controlled-release polymers, and drug-delivery formulation support, competing with TissueGen for pharma licensing and co-development engagements.
  • DSM Biomedical (dsm-firmenich): DSM Biomedical supplies biomedical-grade polymers and drug-eluting device materials to the medical and pharmaceutical industries, overlapping with TissueGen's biodegradable delivery formats and licensing-style customer model.
  • Lubrizol Life Science: Lubrizol Life Science produces engineered polymers and excipients for pharmaceutical drug delivery, including controlled-release systems — a broad incumbent serving the same pharma licensing customer base as TissueGen.
  • Evonik Industries: Evonik's Health Care division supplies RESOMER biodegradable polymers and formulation services for parenteral drug delivery, including sustained-release microparticles and implants — directly overlapping with TissueGen's polymer-based extended-release platform.
  • Corbion: Corbion produces bioresorbable polymers (PURASORB) used in drug delivery and medical devices, and supplies biomaterial inputs comparable to TissueGen's approved-polymer foundation for extended-release therapeutics.

Direct peers

  • PolyPid: PolyPid develops polymer-based drug delivery platforms for localized, prolonged therapeutic release — directly comparable in product architecture and B2B pharma partnership strategy.
  • Innocore Pharmaceuticals: Innocore specializes in biodegradable polymeric drug delivery systems including injectable sustained-release formulations — a closely aligned business model and technology stack to TissueGen's microparticle and fiber platform.
  • Surmodics: Surmodics develops drug-delivery coatings and polymer-based combination products for medical devices and pharmaceuticals, making it a direct peer in polymer-encapsulated, sustained-release therapeutic delivery.

Emerging players

  • Bezwada Biomedical: Bezwada Biomedical develops absorbable polymers and bioabsorbable medical products, including drug-eluting formats, with a smaller-scale, innovation-driven profile comparable to TissueGen's specialist platform approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

TissueGen social profiles

Digital presence

TissueGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TissueGen leadership team

Management profile

Number of profiles

Profiles5 records

TissueGen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TissueGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TissueGen

What does TissueGen do?

TissueGen develops a proprietary two-phase drug delivery platform that uses biodegradable polymers and nanotechnology to encapsulate sensitive biological therapeutics — including antibodies, growth factors, cytokines, and plasmid DNA — into extended-release formats. The company manufactures and licenses drug-eluting fibers, drug-eluting coils, microparticles, and nanoparticles designed to deliver biologics without degradation across nerve, vascular, and ophthalmic applications.

Is TissueGen a public or private company?

TissueGen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TissueGen founded?

TissueGen was founded in 2000. It employs 11 to 50 people.

Where is TissueGen based?

TissueGen is headquartered in Dallas, United States, in the North America region.

How does TissueGen make money?

One revenue line is on record: technology Licensing.

Who are TissueGen's main competitors?

Broad incumbents on record are Pacira BioSciences, Ashland, DSM Biomedical (dsm-firmenich), Lubrizol Life Science, Evonik Industries and Corbion. Direct peers are PolyPid, Innocore Pharmaceuticals and Surmodics. Bezwada Biomedical is listed as an emerging player.

Does TissueGen have an API?

No public API is recorded for TissueGen.

What industry is TissueGen in?

TissueGen's product category is Pharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 3391 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireEdward Parent Appointed Director of Quality Assurance at TissueGenTissueGen appointed Edward Parent as Director of Quality Assurance to guide clinical application and commercial scale-up of its ELUTE fiber technology. Parent brings over 35 years of experience in FDA-regulated environments and has worked with companies like Johnson & Johnson and Genzyme. The company aims to accelerate commercialization of ELUTE fiber-based products.GlobeNewswireTissueGen Wins 2017 Future Textiles Award for Most Innovative Small CompanyTissueGen Inc. won the Most Innovative Small Company award from WTiN at the Future Textiles Gala in Frankfurt. The company's ELUTE fiber is a biodegradable format for drug delivery and tissue engineering, manufactured at or below body temperature to preserve biologics.GlobeNewswireTissueGen Appoints Dr. Jennifer Seifert as Senior Scientist to Lead Spinal Cord Injury Repair ProgramTissueGen appointed Dr. Jennifer Seifert as Senior Scientist to lead its spinal cord injury repair program using ELUTE fiber technology. She joins from the University of Texas at Dallas, and the company is entering Phase II animal trials to validate nerve regeneration. Seifert will apply her research experience to develop treatments for paralysis.GlobeNewswireExpansion and Partnerships Fuel Strong Year for TissueGen in 2013TissueGen launched its first commercially available drug-loaded fiber in Q2 2013 and moved to a new facility with ISO 7 cleanroom capabilities. The company announced a marketing partnership with Biomedical Structures and plans ISO 13485 certification. CEO Christopher Knowles said the company is well-positioned for continued growth.